CPS
  • Home

Sign in or register to track your progress, save, and view your completed history.

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Lung Cancer, Urothelial Cancer

The Nuances of Tumor Types: How are Cutoffs Determined and Validated?

    clockimg 60m
  • Webinar
  • Foundational
 saveimgSave unsaveimgUnsave

The Precision Pathology Insights webinar series brings you expert PD-L1 evaluation insights. Since 2017, the series has provided key perspectives from industry leaders to help sharpen your Combined Positive Score (CPS) expertise and PD-L1 evaluation skills. This webinar is presented by Kristopher Kersch, MD, and Karina Kulangara, PhD. Recorded on 5 November 2020.

 

Dr. Kristopher Kersch and Dr. Karina Kulangara deliver expert insights on the topic of “The Nuances of Tumor Types: How are Cutoffs Determined and Validated?“:

  • Overview of the development process for PD-L1 companion diagnostic assays​
  • Examination of how clinical trials affect cutoffs for companion diagnostics​
  • Validation criteria and important considerations for effectively determining a clinical trial-proven cutoff​
  • Real-World scoring and case examples​

Kristopher Kersch, MD

Pathologist​, Agilent Technologies

Karina Kulangara, PhD​

R&D Director​​, Agilent Technologies

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.​D0113748_1.00